Addition of or switch to insulin therapy in people treated with glucagon-like peptide-1 receptor agonists : a real-world study in 66 583 patients [PDF]
, 2017 Background Real world outcomes of addition or switch to insulin therapy in type 2 diabetes (T2DM) patients on glucagon-like paptide-1 receptor agonist (GLP-1RA) with inadequately controlled hyperglycaemia, are not known.
American Diabetes Association +25 more
core +1 more source
High affinity binding of the peptide agonist TIP-39 to the parathyroid hormone 2 (PTH₂) receptor requires the hydroxyl group of Tyr-318 on transmembrane helix 5 [PDF]
, 2017 TIP39 (“tuberoinfundibular peptide of 39 residues”) acts via the parathyroid hormone 2 receptor, PTH₂, a Family B G protein-coupled receptor (GPCR).
Donnelly, D +4 more
core +1 more source
EClinicalMedicineSummary: Despite the availability of a wide range of antihypertensive agents, a significant proportion of individuals with resistant hypertension (RHTN) struggle to achieve blood pressure (BP) control.
Candace Jarade +3 more
doaj +1 more source
Glucagon-like peptide-1 (GLP-1) mediates cardioprotection by remote ischaemic conditioning [PDF]
, 2016 This work was supported by the British Heart Foundation (Ref: RG/14/4/30736), Medical Research Council (MR/N02589X/1) and The Wellcome Trust (Ref: 200893/Z/16/Z). A.V.G. is a Wellcome Trust Senior Research Fellow. S.M.
Aleksander Mrochek +13 more
core +2 more sources
Hepatocyte-specific HIF-1α ablation improves obesity-induced glucose intolerance by reducing first-pass GLP-1 degradation. [PDF]
, 2019 The decrease in incretin effects is an important etiologic component of type 2 diabetes with unknown mechanisms. In an attempt to understand obesity-induced changes in liver oxygen homeostasis, we found that liver HIF-1α expression was increased mainly ...
Bandyopadhyay, Guatam K +3 more
core
, 2020 The evolution and discovery of a molecule derived from the proglucagon with incretinic effect is described. In the search for a molecule resistant to the rapid metabolism caused by DPP-4, it was found molecules such as Exendin 4 and subsequently the synthetic ones, specific to the GLP-1 receptor and resistant to the metabolism of DPP-4.
openaire +1 more source
Newer GLP-1 receptor agonists and obesity-diabetes
Peptides, 2018 Obesity is a major risk factor for type 2 diabetes and may complicate type 1 diabetes. In parallel with the global epidemic of obesity, the incidence of type 2 diabetes is increasing exponentially. To reverse these alarming trends, weight loss becomes a major therapeutic priority in prevention and treatment of type 2 diabetes.
Brown, Emily +2 more
openaire +2 more sources
Glucagon-like peptide-1 receptor agonists and derivatives in the treatment of obesity - review
Quality in Sport: Obesity is a chronic and insidious disease that represents a significant global. The World Health Organization has announced that almost 60% of European adults are overweight or obese.
Michal Rabenda +6 more
doaj +1 more source
Use and effectiveness of dapagliflozin in routine clinical practice. An Italian multicenter retrospective study [PDF]
, 2018 In randomized controlled trials (RCTs), sodium-glucose co-transporter-2 (SGLT2) inhibitors have been shown to confer glycaemic and extra-glycaemic benefits.
Avogaro A +8 more
core +2 more sources
Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients [PDF]
, 2016 Aims: Treatment with glucagon-like peptide (GLP)-1 receptor agonists or dipeptidyl peptidase (DPP)-4 inhibitors might increase gallstone formation; however, the mechanisms involved are unknown. We aimed to assess the effects of these drugs on gallbladder
Cahen, D.L. (Djuna) +9 more
core +1 more source